Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Shanghai Pulmonary Hospital, Shanghai, China is the lead sponsor of 58 current clinical trials in our China register. 35 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Carboplatin, Benmelstobart and Nab-paclitaxel. The most-studied condition is Lung Cancer.

ClinicalTrials.gov trials by status

Recruiting3560%
Not yet open1831%
Active, closed47%
By invitation12%

Trials by phase

Phase 23052%
Observational1526%
Not applicable712%
Phase 447%
Phase 323%

Clinical trials sponsored by Shanghai Pulmonary Hospital, Shanghai, China

58 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Neoadjuvant Treatment For Locally Advanced Thymic Cancer NCT06019468 · Thymic Carcinoma	Phase 2	Recruiting	2023-11	China
WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma NCT05925764 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma, Whole Slide Image, IASLC Grading System	Observational	Recruiting	2024-10	China
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer NCT05766800 · ClinicalTrials.gov ↗ · Locally Advanced, Non-small Cell Lung Cancer Drugs: Carboplatin, Liposomal paclitaxel, Nab-paclitaxel	Phase 2	Recruiting	2023-03	China
T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPD NCT07823842 · ClinicalTrials.gov ↗ · Asthma, COPD (Chronic Obstructive Pulmonary Disease)	Observational	Recruiting	2026-07	China
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% NCT03351842 · ClinicalTrials.gov ↗ · Chemotherapy, Adjuvant, Lung Adenocarcinoma, Stage I, Treatment	Phase 2	Recruiting	2017-09	China
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer NCT06758700 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms, Lung Neoplasms	Phase 2	Recruiting	2025-02	China
Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm NCT05838053 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma	Observational	Recruiting	2019-08	China
Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma NCT06528847 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drug: Benmelstobart	Phase 2	Recruiting	2024-06	China
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer NCT07323056 · ClinicalTrials.gov ↗ · EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable	Phase 2	Recruiting	2026-01	China
Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine NCT07134660 · ClinicalTrials.gov ↗ · Postoperative Pain, Acute, Lung Cancer	Not applicable	Recruiting	2025-09	China
Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study NCT06216782 · ClinicalTrials.gov ↗ · Lung Cancer	Observational	Recruiting	2023-12	China
Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer NCT07328945 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Observational	Recruiting	2023-12	China
Robot-assisted vs VATS for Thymoma NCT06029621 · ClinicalTrials.gov ↗ · Thymoma	Not applicable	Recruiting	2023-11	China
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer NCT07410975 · ClinicalTrials.gov ↗ · NSCLC Stage II, NSCLC Stage III Drugs: Ipilimumab N01, Sintilimab	Phase 2	Recruiting	2026-01	China
Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study NCT07243873 · ClinicalTrials.gov ↗ · Lung Cancer, PET-CT	Observational	Recruiting	2025-12	China
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients NCT07820254 · ClinicalTrials.gov ↗ · Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis	Observational	Recruiting	2026-01	China
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy NCT06780826 · ClinicalTrials.gov ↗ · Lung Cancer, Small Cell	Observational	Recruiting	2024-08	China
Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function NCT07309393 · ClinicalTrials.gov ↗ · Residual Neuromuscular Block Drug: Neostigmine	Not applicable	Recruiting	2025-12	China
Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial NCT05053802 · ClinicalTrials.gov ↗ · Multiple Primary Lung Cancer	Phase 2	Recruiting	2021-03	China
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma NCT05503667 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Drugs: Bevacizumab, Furmonertinib	Phase 2	Recruiting	2022-02	China
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease NCT05824988 · ClinicalTrials.gov ↗ · Mycobacterium Avium Complex, Mycobacterium Avium-Intracellulare Infection, Gram-Positive Bacterial Infections	Observational	Recruiting	2023-04	China
Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment NCT05857800 · ClinicalTrials.gov ↗ · Lung Cancer	Observational	Recruiting	2023-05	China
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression NCT06749860 · ClinicalTrials.gov ↗ · Lung Cancer Drugs: Bevacizumab, Disitamab Vedotin, Tislelizumab	Phase 2	Recruiting	2024-02	China
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB NCT05493267 · ClinicalTrials.gov ↗ · MDR-TB, Immunotherapy	Phase 4	Recruiting	2022-08	China
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial NCT06256237 · ClinicalTrials.gov ↗ · Limited Stage Small Cell Lung Cancer	Phase 2	Recruiting	2024-04	China
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer NCT04539977 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer Drugs: Benmelstobart, Carboplatin, Etoposide	Phase 2	Recruiting	2020-09	China
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer NCT07408635 · ClinicalTrials.gov ↗ · Unresectable Stage III Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)	Phase 2	Recruiting	2026-01	China
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm NCT04937283 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma	Not applicable	Recruiting	2019-10	China
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC NCT07754812 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer) Drug: Paclitaxel	Phase 4	Recruiting	2026-06	China
The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping NCT06900062 · ClinicalTrials.gov ↗ · Bronchiectasis Adult	Observational	Recruiting	2025-04	China
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer NCT05965024 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Observational	Recruiting	2023-10	China
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting NCT06749886 · ClinicalTrials.gov ↗ · Lung Cancer Drugs: Denosumab, Docetaxel, Tislelizumab	Phase 2	Recruiting	2024-11	China
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients NCT06987734 · ClinicalTrials.gov ↗ · Lung Cancer (NSCLC)	Phase 2	Recruiting	2025-06	China
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer NCT04728724 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage III Drug: Sintilimab	Phase 2	Recruiting	2022-09	China
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II) NCT06760273 · ClinicalTrials.gov ↗ · Bronchiectasis Adult	Observational	Recruiting	2024-10	China
A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens NCT07469488 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism), Rash Due to Epidermal Growth Factor Receptor Inhibitors	Phase 4	Not yet open	2026-04	China
Efficacy and Safety of Huanjingjian Decoction in Women With Premature Ovarian Insufficiency NCT07020429 · ClinicalTrials.gov ↗ · Premature Ovarian Insufficiency	Not applicable	Not yet open	2025-09	China
Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial NCT07517640 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drug: Furmonertinib	Phase 2	Not yet open	2026-04	China
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer NCT06648200 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent	Phase 2	Not yet open	2024-11	China
A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy NCT07101627 · ClinicalTrials.gov ↗ · Lung Cancer Drug: Hetrombopag	Phase 2	Not yet open	2025-08	China
Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT NCT07169903 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma	Phase 3	Not yet open	2025-10	China
A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study NCT07375979 · ClinicalTrials.gov ↗ · Lung Cancer	Observational	Not yet open	2026-02	China
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033 NCT07097948 · ClinicalTrials.gov ↗ · Postoperative Incidental Small Cell Lung Cancer, Toripalimab Adjuvant Therapy Evaluation Drugs: Etoposide, Toripalimab	Phase 2	Not yet open	2025-08	China
TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery NCT07494591 · ClinicalTrials.gov ↗ · Ipsilateral Shoulder Pain, Video-Assisted Thoracoscopic Surgery	Not applicable	Not yet open	2026-04	China
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC NCT06837948 · ClinicalTrials.gov ↗ · Locally Advanced Non-Small Cell Lung Cancer Drugs: Carboplatin, Nab-paclitaxel, Pumitamig	Phase 2	Not yet open	2025-02	China
Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients NCT07493980 · ClinicalTrials.gov ↗ · NSCLC Stage II Drugs: Carboplatin, JSKN016, Toripalimab	Phase 2	Not yet open	2026-03	China
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer NCT06109402 · ClinicalTrials.gov ↗ · Stage II-IIIB(N2) Non-small Cell Lung Cancer Drugs: Benmelstobart, Carboplatin, Nab-paclitaxel	Phase 2	Not yet open	2023-12	China
The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer NCT05496166 · ClinicalTrials.gov ↗ · Limited Stage Small Cell Lung Cancer	Phase 3	Not yet open	2023-08	China
Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) NCT07393438 · ClinicalTrials.gov ↗ · Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis, MDR-TB	Phase 2	Not yet open	2026-02	China
Application of Electromagnetic Navigation System in Pulmonary Nodule Localization NCT07595120 · ClinicalTrials.gov ↗ · Pulmonary Nodules, Early-Stage Lung Cancer	Not applicable	Not yet open	2026-05	China
Intrapleural Bupivacaine Analgesia for Postoperative Pain Management After Minimally Invasive Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial NCT07393386 · ClinicalTrials.gov ↗ · Pain Management Drug: Bupivacaine	Phase 4	Not yet open	2026-02	China
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial NCT06620822 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Not yet open	2024-09	China
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC NCT06585644 · ClinicalTrials.gov ↗ · Lung Cancer (NSCLC)	Phase 2	Not yet open	2024-10	China
The Effect of Semi-recumbent Position on Hypoxemia After Lung Segment/Lobe Surgery NCT07060625 · ClinicalTrials.gov ↗ · Lung Cancer (Diagnosis), Hypoxemia	Observational	By invitation	2024-12	China
Toripalimab Combined With SBRT for NSCLC NCT06293690 · ClinicalTrials.gov ↗ · Non-small Lung Cancer Drugs: SBRT, Toripalimab	Phase 2	Active, closed	2024-04	China
Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation. NCT07274761 · ClinicalTrials.gov ↗ · Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Drug: Sunvozertinib	Phase 2	Active, closed	2024-10	China
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer NCT04379739 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	2020-07	China
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer NCT04685070 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage III Drug: Almonertinib	Phase 2	Active, closed	2021-12	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Shanghai Pulmonary Hospital, Shanghai, China trials

25 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Shanghai Pulmonary Hospital, Shanghai, China trials

72 conditions

Lung Cancer8 Non-small Cell Lung Cancer4 Lung Adenocarcinoma4 Non Small Cell Lung Cancer3NSCLC Stage II2Limited Stage Small Cell Lung Cancer2MDR-TB2Non-small Cell Lung Cancer Stage III2Lung Cancer (NSCLC)2Bronchiectasis Adult2Thymic Carcinoma1NSCLC (Advanced Non-small Cell Lung Cancer)1VTE (Venous Thromboembolism)1Rash Due to Epidermal Growth Factor Receptor Inhibitors1Infusion Reaction1Premature Ovarian Insufficiency1Whole Slide Image1IASLC Grading System1Artificial Intelligence1Locally Advanced1Small Cell Lung Cancer Extensive Stage1Small Cell Lung Cancer Recurrent1Asthma1 COPD (Chronic Obstructive Pulmonary Disease)1

By trial register

Register	Trials	Recruiting
Clinical trials in China	58	35

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Lung Cancer

Sponsor	Trials
Second Affiliated Hospital of Guangzhou Medical University	10
Shanghai Chest Hospital	9
The First Affiliated Hospital of Guangzhou Medical University	6
Intuitive Surgical	4
Guangdong Provincial People's Hospital	3
The Fourth Affiliated Hospital of Zhejiang University School of Medicine	3
All India Institute of Medical Sciences	2
Liu Huang	2
Zhou Chengzhi	2
Queen's University, Belfast	1

Sponsors with the most current trials registered for this condition.

Questions about Shanghai Pulmonary Hospital, Shanghai, China trials

How many clinical trials does Shanghai Pulmonary Hospital, Shanghai, China sponsor?

Shanghai Pulmonary Hospital, Shanghai, China is the lead sponsor of 58 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai Pulmonary Hospital, Shanghai, China trials recruiting?

Yes. 35 of its 58 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Pulmonary Hospital, Shanghai, China testing?

Its current trials name 25 drugs and biologicals as interventions. The most frequent are Carboplatin (5), Benmelstobart (3), Nab-paclitaxel (3), Sintilimab (3) and Toripalimab (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Shanghai Pulmonary Hospital, Shanghai, China clinical trials